![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
No clinically significant interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and the immunosuppressive agents cyclosporine and tacrolimus
|
|
|
Reported by Jules Levin
AASLD Nov 2012 Boston
S Ouwerkerk-Mahadevan,1 A Simion,2 S Mortier,2
M Peeters,2 M Beumont-Mauviel2
1Janssen Research and Development, Beerse, Belgium; 2Janssen Infectious Diseases, Beerse, Belgium
![AASLD1.gif](../../2013/images/010713/010713-6/AASLD1.gif)
![AASLD2.gif](../../2013/images/010713/010713-6/AASLD2.gif)
![AASLD3.gif](../../2013/images/010713/010713-6/AASLD3.gif)
![AASLD4.gif](../../2013/images/010713/010713-6/AASLD4.gif)
![AASLD5.gif](../../2013/images/010713/010713-6/AASLD5.gif)
![AASLD6.gif](../../2013/images/010713/010713-6/AASLD6.gif)
![AASLD7.gif](../../2013/images/010713/010713-6/AASLD7.gif)
![AASLD8.gif](../../2013/images/010713/010713-6/AASLD8.gif)
![AASLD9.gif](../../2013/images/010713/010713-6/AASLD9.gif)
![AASLD10.gif](../../2013/images/010713/010713-6/AASLD10.gif)
![AASLD11.gif](../../2013/images/010713/010713-6/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|